Gilead Sciences Inc. placed another big bet in fibrosis, inking a preclinical deal with Scholar Rock Holding Corp. that includes $80 million up front – $50 million in cash and $30 million in Scholar Rock common shares – along with a one-time milestone payment of $25 million when certain preclinical studies are completed. Read More
There are many proteins in humans, bacteria and viruses that would make great targets to shut down a pathway to treat a disease or stop an infection, but, for a variety of reasons, designing drugs to target those proteins has been difficult. Read More
DUBLIN – Investors in Molecular Partners AG received a much-needed boost Wednesday as the company entered an immuno-oncology collaboration with Amgen to develop its preclinical multispecific Darpin molecule MP0310, in return for $50 million up front and up to $497 million in development, regulatory and commercial milestones, plus tiered double-digit royalties on product sales. Read More
Aduro Biotech Inc.'s research and licensing deal with Eli Lilly and Co. not only provides $12 million up front and potential milestone-related money in the amount of $620 million per product – for an unlimited number of them – but also includes a "nice modularity," as Chief Scientific Officer Andrea van Elsas put it, in the form of an option to co-fund development. Read More
HONG KONG – China-based ophthalmology startup Ocumension Therapeutics Ltd. has inked a deal for potentially €36.25 million (US$41.35 million) to develop and commercialize French counterpart Nicox SA's NCX470 in the Chinese mainland, Hong Kong, Macau and Taiwan. Read More
Although developers of novel cancer therapeutics, particularly in the immuno-oncology area, have managed to attract the lion's share of investment funding and partnerships, that enthusiasm has not translated to the capital markets. Read More
Sutro Biopharma Inc., of South San Francisco, received a $10 million milestone payment from Celgene Corp., of Summit, N.J., for the successful development of a dry powder Xtractcf formulation. Read More
Pandion Therapeutics Inc., of Cambridge, Mass., said it received an investment from the JDRF T1D Fund that will enable the company to launch a type 1 diabetes (T1D)-focused program leveraging its technology platform and pipeline. Read More
Pennsylvania Attorney General Josh Shapiro and Governor Tom Wolf said the state launched an on-line tool to report suspicious activity regarding prescription drugs. Read More
